On Wednesday, Guidewire Software Inc (NYSE:GWRE)’s shares inclined 11.77% to $52.98.
Guidewire Software Inc (GWRE) declared its financial results for the fiscal quarter ended April 30, 2015.
Third Quarter Fiscal 2015 Financial Highlights
Revenue
- License revenue for the third quarter of fiscal 2015 was $33.3 million, contrast to $31.9 million in the same period in fiscal 2014. Maintenance revenue was $12.2 million, contrast to $10.4 million in the same period in fiscal 2014. Services revenue was $40.0 million, contrast to $39.7 million in the same period in fiscal 2014. Total revenue was $85.4 million, contrast to $82.0 million in the same period in fiscal 2014.
- License revenue for the nine month period of fiscal 2015 was $105.8 million, contrast to $86.0 million in the same period in fiscal 2014. Maintenance revenue was $36.9 million, contrast to $30.0 million in the same period in fiscal 2014, and Services revenue was $112.0 million, contrast to $116.0 million in the same period in fiscal 2014. Total revenue was $254.6 million, contrast to $232.0 million in the same period in fiscal 2014.
- Rolling four-quarter recurring term license and maintenance revenue was $208.9 million, an enhance of 26% contrast to the period ending April 30, 2014.
Profitability
- The GAAP operating loss was $6.7 million for the third quarter of fiscal 2015, contrast with operating income $0.1 million in the comparable period in fiscal 2014.
- Non-GAAP operating income was $6.1 million for the third quarter of fiscal 2015, contrast with $10.9 million in the comparable period in fiscal 2014.
- The GAAP net loss was $3.0 million for the third quarter of fiscal 2015, contrast with a net loss of $1.9 million for the comparable period in fiscal 2014. GAAP net loss per share was $0.04, based on diluted weighted average shares outstanding of 70.3 million, contrast with a net loss of $0.03 per share for the comparable period in fiscal 2014, based on diluted weighted average shares outstanding of 68.3 million.
Guidewire Software, Inc. provides software products for property and casualty (P&C) insurers. It offers an integrated suite of software applications that address the core processes, such as underwriting and policy administration, claims administration, and billing.
CME Group Inc (NASDAQ:CME)’s shares gained 0.23% to $94.52.
CME Group Inc (CME) declared that Executive Chairman and President Terry Duffy and Chief Financial Officer John Pietrowicz will present at the Sandler O’Neill 2015 Global Exchange and Brokerage Conference, in New York, at Le Parker Meridien, on Thursday, June 4, 2015, at 3:00 p.m. (Eastern Time).
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals.
At the end of Wednesday’s trade, Tiffany & Co. (NYSE:TIF)‘s shares dipped -0.11% to $93.92.
The Board of Directors of Tiffany & Co. (TIF) has declared a regular quarterly dividend of $0.40 per share of Common Stock, representing a 5% enhance in the quarterly rate. This action enhances the quarterly dividend from $0.38 per share (or $1.52 annually) to the new rate of $0.40 per share (or $1.60 annually).
Tiffany & Co., through its auxiliaries, designs, manufactures, and retails jewelry worldwide. Its jewelry products comprise fine and solitaire jewelry; engagement rings and wedding bands to brides and grooms; and non-gemstone, sterling silver, gold, and metal jewelry. The company also sells timepieces, leather goods, sterling silverware, china, crystal, stationery, fragrances, and accessories. In addition, it wholesales diamonds to third parties.
Great Basin Scientific Inc (NASDAQ:GBSN), ended its Wednesday’s trading session with 3.66% gain, and closed at $3.68.
Great Basin Scientific, Inc. ( GBSN), a molecular diagnostics company, recently declared the election of Kirk Calhoun to its Board of Directors, effective May 27, 2015. Mr. Calhoun was elected to the board as an independent director during the Company’s Annual Stockholder Meeting on May 27 in Salt Lake City. He will serve as the chair of the Company’s Audit Committee. Mr. Calhoun joins Ryan Ashton, David Spafford, Ronald K. Labrum and Sam Chawla on the board, and replaces Steven Aldous, who is retiring from his director position .
Mr. Calhoun is a Certified Public Accountant (non-practicing) with a background in auditing and accounting. Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965 and served as a partner of the firm from 1975 until his retirement in 2002. Mr. Calhoun presently serves on the board and audit committee of Response Genetics, Inc. (RGDX) and Ryerson Holding Corporation (RYI). Mr. Calhoun has served formerly on the boards and audit committees of five public companies in the pharmaceutical industry up until the dates of their respective sales, counting Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. and Adams Respiratory Therapeutics, Inc. Mr. Calhoun also presently serves on the boards of three private companies, counting NeuroSigma, Inc., a developer of products that treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Mr. Calhoun received a B.S. in Accounting from the University of Southern California.
Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections. The company’s platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
